TTR and amyloidosis: Mounting clinical and preclinical evidence indicated that tafamidis and diflunisal reduced the progression of early- and late-onset ATTRwt and Val30Met (ATTRV30M) amyloidoses and diseases associated with other TTR variants (Bulawa et al., 2012; Berk et al., 2013).